Zinc sulphate therapy for Wilson's disease after acute deterioration during treatment with low-dose D-penicillamine.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 2045766.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A 30-year-old woman with Wilson's disease was treated with low-dose D-penicillamine. After 12 days, treatment was changed to zinc sulphate because of severe neurological deterioration. The patient subsequently improved within a few days. During a follow-up period of 20 months, the effectiveness of therapy was evaluated by measuring copper and zinc levels in plasma and urine, and by 64Cu-loading tests. We conclude that sulphate therapy may be a satisfactory alternative, even when rapid deterioration occurs in the early stages of D-penicillamine treatment.
Medical subject headings
- Adult
- Brain Diseases
- Brain Diseases/chemically induced
- Copper
- Copper/blood
- Copper/urine
- Female
- Hepatolenticular Degeneration
- Hepatolenticular Degeneration/blood
- Hepatolenticular Degeneration/drug therapy
- Hepatolenticular Degeneration/urine
- Humans
- Penicillamine
- Penicillamine/adverse effects
- Sulfates
- Sulfates/therapeutic use
- Zinc
- Zinc/blood
- Zinc/therapeutic use
- Zinc/urine
- Zinc Sulfate